Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Director, Research collaborations, Elsevier
About the author:
Mark is developing and managing Elsevier’s flagship partnerships in Europe and Life Sciences around e.g. Artificial Intelligence or Research integrity. Examples are the launch of Elsevier’s AI lab as part of Amsterdam Data Science or the joint innovation center with Humboldt University Berlin. He is a co-author of Elsevier’s recognized AI report.
He has a research background (PhD) in Business Informatics (Semantic Search) from the University of Kaiserslautern, Germany. He holds a Technical Master in Business Administration from University of Stuttgart, Germany.
He led the Public Sector business with eGovernment solutions for the IT Solution business of Siemens AG in Germany. Besides various managerial and business development roles in Siemens he set-up with his own start-up a platform for language courses during the new economy.
Mark developed Elsevier’s global engagement with leading research institutions, such as Harvard, Oxford and with commercial partners in emerging markets. He has a strong personal interest in digital transformation, knowledge management, complex systems research and societal impact of science.
Posts by Mark Siebert
Posted on March 19th, 2020 in Pharma R&D
Health data is everywhere. It is managed by universities, research centers, medical institutions and by individuals themselves. With this valuable data located in so many disparate places, and organized differently in each place, it can be difficult for researchers to access and make use of it.(more…)
Posted on January 29th, 2020 in Pharma R&D
Amsterdam, a vibrant and renowned cultural destination, has also been enlarging its reputation as an innovative scientific hub. A series of big new national initiatives, including the corporate Kickstart AI program and the academia-driven AI Technology for People initiative (which is making “AI for Health” one of its main priorities), have put the focus squarely on artificial intelligence.(more…)
Posted on January 17th, 2020 in Pharma R&D
Artificial intelligence are the words on everyone’s lips these days. Across industries, AI is driving some of today’s most exciting innovations and is poised to be ubiquitous in the future. But success in AI demands investment, and now is the time to put up those funds in order to secure the brightest minds and best companies. That’s why Amsterdam’s educational institutions and knowledge centers are joining forces and pledging one billion euros for AI.(more…)